Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE versus MECLOFENAMATE SODIUM.
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
1 tablet (ibuprofen 200 mg/phenylephrine HCl 10 mg) orally every 4-6 hours as needed, not to exceed 6 tablets per 24 hours.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Ibuprofen: 2-4 hours (prolonged in overdose or hepatic impairment). Phenylephrine: 2-3 hours (clinical activity may persist longer due to vasoconstrictive effects).
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Ibuprofen: Renal elimination of metabolites (90%) and unchanged drug (1-10%); biliary/fecal excretion minor. Phenylephrine: Renal elimination (80-85% as inactive metabolites, 2-3% unchanged); biliary/fecal negligible.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category D/X
Category C
NSAID
NSAID